StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

Kiniksa Pharmaceuticals International operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Kiniksa Pharmaceuticals International's operating cash flow for the twelve months ending Sep 30, 2026 was $198.84M, up 93.3% year over year. For fiscal 2025 it was $137.99M, up 437.1% from the year before. The highest annual figure on record is $137.99M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$137.99M+437.1%
FY2024Dec 31, 2024$25.69M+93.1%
FY2023Dec 31, 2023$13.30M+129.1%
FY2022Dec 31, 2022$5.81M–
FY2021Dec 31, 2021-$126.30M–
FY2020Dec 31, 2020-$136.53M–
FY2019Dec 31, 2019-$158.37M–
FY2018Dec 31, 2018-$81.01M–
FY2017Dec 31, 2017-$50.22M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$47.55M+41.2%
Q2 FY2026Jun 30, 2026$47.20M+68.0%
Q1 FY2026Mar 31, 2026$50.20M+124.9%
Q4 FY2025Dec 31, 2025$53.89M+187.1%
Q3 FY2025Sep 30, 2025$33.68M–
Q2 FY2025Jun 30, 2025$28.09M+443.5%
Q1 FY2025Mar 31, 2025$22.32M+459.9%
Q4 FY2024Dec 31, 2024$18.77M+334.0%
Q3 FY2024Sep 30, 2024-$2.24M-113.2%
Q2 FY2024Jun 30, 2024$5.17M–
Q1 FY2024Mar 31, 2024$3.99M–
Q4 FY2023Dec 31, 2023$4.33M–
Q3 FY2023Sep 30, 2023$16.99M-72.6%
Q2 FY2023Jun 30, 2023-$3.74M–
Q1 FY2023Mar 31, 2023-$4.27M–
Q4 FY2022Dec 31, 2022-$11.58M–
Q3 FY2022Sep 30, 2022$62.05M–
Q2 FY2022Jun 30, 2022-$7.82M–
Q1 FY2022Mar 31, 2022-$36.85M–
Q4 FY2021Dec 31, 2021-$18.88M–
Q3 FY2021Sep 30, 2021-$28.51M–
Q2 FY2021Jun 30, 2021-$38.78M–
Q1 FY2021Mar 31, 2021-$40.12M–
Q4 FY2020Dec 31, 2020-$41.19M–
Q3 FY2020Sep 30, 2020-$34.32M–
Q2 FY2020Jun 30, 2020-$29.22M–
Q1 FY2020Mar 31, 2020-$31.80M–
Q4 FY2019Dec 31, 2019-$24.17M–
Q3 FY2019Sep 30, 2019-$29.27M–
Q2 FY2019Jun 30, 2019-$41.68M–
Q1 FY2019Mar 31, 2019-$63.26M–
Q4 FY2018Dec 31, 2018-$27.64M–
Q3 FY2018Sep 30, 2018-$20.49M–
Q2 FY2018Jun 30, 2018-$17.92M–
Q1 FY2018Mar 31, 2018-$14.97M–
Q4 FY2017Dec 31, 2017-$23.38M–
Q3 FY2017Sep 30, 2017-$10.94M–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?